175 reports of this reaction
1.6% of all CALCIUM CARBONATE, MAGNESIUM HYDROXIDE reports
#11 most reported adverse reaction
TUBULOINTERSTITIAL NEPHRITIS is the #11 most commonly reported adverse reaction for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, manufactured by THE PROCTER & GAMBLE MANUFACTURING COMPANY. There are 175 FDA adverse event reports linking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE to TUBULOINTERSTITIAL NEPHRITIS. This represents approximately 1.6% of all 10,871 adverse event reports for this drug.
Patients taking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE who experience tubulointerstitial nephritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TUBULOINTERSTITIAL NEPHRITIS is a less commonly reported adverse event for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, but still significant enough to appear in the safety profile.
In addition to tubulointerstitial nephritis, the following adverse reactions have been reported for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE:
The following drugs have also been linked to tubulointerstitial nephritis in FDA adverse event reports:
TUBULOINTERSTITIAL NEPHRITIS has been reported as an adverse event in 175 FDA reports for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TUBULOINTERSTITIAL NEPHRITIS accounts for approximately 1.6% of all adverse event reports for CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, making it a notable side effect.
If you experience tubulointerstitial nephritis while taking CALCIUM CARBONATE, MAGNESIUM HYDROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.